江苏恒瑞医药股份有限公司

Chinese pharmaceutical company headquartered in Lianyungang, Jiangsu and listed on the Shanghai Stock Exchange under code 600276 and in Hong Kong under code 1276, and the largest research based pharmaceutical company in China by revenue. Discovers, develops, manufactures and sells medicines across oncology, anaesthesia and analgesia, contrast media, autoimmune disease, metabolic disease and infectious disease, with marketed innovative products including the PD-1 antibody camrelizumab, the CDK4/6 inhibitor dalpiciclib and the ADC medicine SHR-A1811 alongside a large generic and injectable portfolio. Runs research centres in Lianyungang, Shanghai, Chengdu and the United States, and has out-licensed several assets to international partners.